Elevation Oncology (ELEV) Prices 6.25M Share IPO at $16/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
Elevation Oncology Announces Pricing of Initial Public Offering
June 24, 2021 8:44 PM EDTNEW YORK, June 24, 2021 /PRNewswire/ --Â Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $16.00Â per share. All of the shares are being offered by Elevation Oncology. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Elevation Oncology, are expected to be $100 million. The shares... More
